Jiao Zhihao, Huang Yongmi, Gong Kexin, Liu Yiru, Sun Jinxiao, Yu Shangzhe, Zhao Guisen
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, PR China.
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, PR China.
Bioorg Chem. 2024 Dec;153:107859. doi: 10.1016/j.bioorg.2024.107859. Epub 2024 Oct 1.
Protein arginine methyltransferase 5 (PRMT5) is a type II PRMT enzyme that plays an important role in protein formation. PRMT5 is widely distributed in the nucleus and is involved in regulating a variety of biological processes, including gene transcription, signaling, and cell proliferation. PRMT5 regulates the function and stability of histones through methylation, affecting important cellular activities such as cell cycle regulation, DNA repair, and RNA processing. Studies have shown that PRMT5 is overexpressed in a variety of tumors and is closely related to the occurrence and development of tumors. In recent years, several PRMT5 inhibitors have entered clinical trials for the treatment of various cancers. In view of their importance, this paper reviews the first generation of PRMT5 inhibitors obtained by high-throughput screening, virtual screening, lead compound optimization and substitution modification, as well as novel PRMT5 inhibitors obtained by PROTAC technology and by synthetic lethal principle. Finally, by comparing the differences between the first generation and the second generation, the challenges and future development directions of PRMT5 inhibitors are discussed.
蛋白质精氨酸甲基转移酶5(PRMT5)是一种II型PRMT酶,在蛋白质形成中起重要作用。PRMT5广泛分布于细胞核中,参与调节多种生物学过程,包括基因转录、信号传导和细胞增殖。PRMT5通过甲基化调节组蛋白的功能和稳定性,影响细胞周期调控、DNA修复和RNA加工等重要细胞活动。研究表明,PRMT5在多种肿瘤中过表达,与肿瘤的发生发展密切相关。近年来,几种PRMT5抑制剂已进入治疗各种癌症的临床试验。鉴于它们的重要性,本文综述了通过高通量筛选、虚拟筛选、先导化合物优化和取代修饰获得的第一代PRMT5抑制剂,以及通过PROTAC技术和合成致死原理获得的新型PRMT5抑制剂。最后,通过比较第一代和第二代之间的差异,讨论了PRMT5抑制剂面临的挑战和未来发展方向。